Bing Yan

Bing Yan

Auto-generated profile, based on publicly available information

Bing Yan

Department of Otolaryngology, Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2020 in Expert Review of Clinical Immunology
Verified
Journal Article
Closed access
CWChengshuo Wang
Chengshuo Wang
BYBing Yan
Bing Yan
LZLuo Zhang
Luo Zhang
Introduction: Chronic rhinosinusitis with nasal polyps (CRSwNP) is an inflammatory airway disease characterized as tight junction loosening, inflammation, and mucosal remodeling. Epithelial cells form a barrier against allergens, bacteria, and proteases, and can also trigger or enhance the immune response by releasing various inflammatory mediators including cytokines, chemokines, and secreted proteins to promote the pathogenesis of CRSwNP. Areas covered: We review the epithelium-derived cytokine and secreted protein networks driving CRSwNP, and discuss these mediators in a cellular context. We illustrate their roles as potential mediators-biomarkers in clinical practice, which may help to understand the mechanisms underlying the pathologies of different endotypes of CRSwNP and to improve treatment outcomes in patients with CRSwNP based on the development of novel predictors for CRSwNP management. Expert opinion: The understanding of the role of epithelium-derived inflammatory mediators helps to investigate the pathophysiological mechanisms of CRSwNP endotypes. An increasing number of studies show that these mediators target immune cells and promote the recruitment, activation or regulation of the proliferation or apoptosis of these cells. Based on this achievement, further investigations are necessary to explore the multi-dimensional role of epithelium-derived inflammatory mediators in CRSwNP.

29 September 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
MXMu Xian
Mu Xian
FLFeng Lan
Feng Lan
BYBing Yan
Bing Yan
SSShen Shen
Shen Shen
SLShixi Liu
Shixi Liu
LZLuo Zhang
Luo Zhang
To explore the therapeutic potential of blocking thymic stromal lymphopoietin (TSLP) in patients with chronic rhinosinusitis with nasal polyps (CRSwNP), we conducted a phase 1b/2a, randomized, double-blind, placebo-controlled trial to assess the safety and efficacy of CM326, a monoclonal antibody against TSLP. We enrolled 84 eligible patients with uncontrolled CRSwNP and stratified them based on baseline tissue eosinophil count. Patients are assigned to receive CM326 220 mg (n = 40) or placebo (n = 20) every 2 weeks (Q2W) and CM326 220 mg (n = 20) or placebo (n = 4) every 4 weeks (Q4W) for 16 weeks. Subsequently, all patients continue on CM326 220 mg Q2W or Q4W for an additional 36 weeks, followed by a 12-week follow up. Primary endpoints are safety of CM326 and change from baseline in NPS at week 16 in patients with eosinophilic CRSwNP (ECRSwNP). Main secondary endpoints include the change from baseline in NPS at week 16 in non-eosinophilic CRSwNP (nonECRwNP) and pharmacodynamic markers. Throughout the 64-week study, all treatment-emergent adverse events (TEAEs) are mild or moderate. CM326 Q2W improves NPS in patients with ECRSwNP compared with placebo at week 16 (mean difference [95% CI], −1.2 [−2.3 to −0.1], P = 0.04), with sustained benefits during the open-label and follow-up periods. Notably, peripheral blood and tissue eosinophil counts and concentrations of plasma IL-13 and IL-5 are reduced by week 16 with the treatment of CM326 Q2W versus placebo. A post-hoc analysis demonstrates that all participants with baseline TSLP > 330 fg/mL achieve a substantial reduction in NPS by week 16 with the treatment of CM326 Q2W (mean difference vs. placebo: −1.75 [95%CI, −3.06 to −0.44], P = 0.01). Overall, CM326 is well tolerated and effective in patients with uncontrolled ECRSwNP. A baseline plasma TSLP level of 330 fg/mL may serve as a predictive marker for treatment efficacy of CM326. ClinicalTrials.gov Identifier: NCT05324137.

11 December 2023 in Allergy
Verified
Journal Article
Closed access
LSLinping Shu
Linping Shu
QHQunshan He
Qunshan He
BYBing Yan
Bing Yan
DWDi Wu
Di Wu
MWMenglin Wang
Menglin Wang
LZLuo Zhang
Luo Zhang

7 May 2024 in European Archives of Oto-Rhino-Laryngology
Verified
Journal Article
Closed access
PDF file
YRYimin Ren
Yimin Ren
GFGaoli Fang
Gaoli Fang
KWKuiji Wang
Kuiji Wang
BYBing Yan
Bing Yan
Chengshuo WangChengshuo Wang
Chengshuo Wang


21 October 2026 in Asia Pacific Allergy
Verified
Journal Article
Open access
YLYing Li
Ying Li
YHYuqing Huang
Yuqing Huang
MZMenglu Zhang
Menglu Zhang
JYJiangchuan Ye
Jiangchuan Ye
Chengshuo WangChengshuo Wang
Chengshuo Wang
LZLuo Zhang
Luo Zhang
Background: 15(S)-HETE, a bioactive lipid mediator derived from arachidonic acid, is closely associated with eosinophilic inflammation and recurrence in chronic rhinosinusitis with nasal polyps (CRSwNP). Nevertheless, its impact on fibroblast-associated transcriptional regulation remains poorly characterized. Objective: To characterize the transcriptional and immunologic alterations in fibroblasts following 15(S)-HETE exposure. Methods: Human fibroblasts (MRC-5) were exposed to either 15(S)-HETE or a dimethyl sulfoxide vehicle control before RNA sequencing. Differential expression analysis was combined with Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway annotation to characterize functional alterations. Pathway-level transcriptional changes were additionally explored using gene set enrichment analysis and weighted gene co-expression network analysis. Fibroblast viability was further assessed with a Cell Counting Kit-8 assay. Results: Transcriptomic profiling of the 15(S)-HETE-treated group revealed 96 differentially expressed genes, consisting of 54 upregulated and 42 downregulated genes. Upregulated genes were enriched in cytokine-related and inflammatory pathways, particularly interleukin-17 and tumor necrosis factor signaling. In contrast, downregulated genes were mainly involved in interferon-mediated antiviral responses. Gene set enrichment analysis further revealed significant suppression of interferon-α and interferon-γ response signatures. Weighted Gene Co-expression Network Analysis identified inflammation-related gene modules associated with 15(S)-HETE stimulation, in which CXCL1 was upregulated. In addition, 15(S)-HETE treatment significantly increased fibroblast viability. Conclusion: 15(S)-HETE was associated with changes in fibroblast transcriptional programs, including reduced interferon-related signatures and increased cytokine signaling. These findings suggest a potential role for 15(S)-HETE in fibroblast-associated immune regulation relevant to CRSwNP.